{Reference Type}: Journal Article
{Title}: Multi-stakeholder consensus on a target product profile for an HIV cure.
{Author}: Lewin SR;Attoye T;Bansbach C;Doehle B;Dubé K;Dybul M;SenGupta D;Jiang A;Johnston R;Lamplough R;McCune JM;Nabel GJ;Ndung'u T;Pottage J;Ripin D;Rooney JF;Sikazwe I;Nsubuga M;Warren M;Deeks SG; ;
{Journal}: Lancet HIV
{Volume}: 8
{Issue}: 1
{Year}: 01 2021
{Factor}: 16.07
{DOI}: 10.1016/S2352-3018(20)30234-4
{Abstract}: Developing a cure for HIV is a global priority. Target product profiles are a tool commonly used throughout the drug development process to align interested parties around a clear set of goals or requirements for a potential product. Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy. An intervention that successfully cured a reasonable fraction of adults would be sufficient to advance to the clinic. These target product profiles will require further discussion and ongoing revisions as the field matures.